Evidence map›Paper›PMID 25036743›Full record

ArticleJournal of lower genital tract disease2015

Responses to the McGill Pain Questionnaire predict neuropathic pain medication use in women in with vulvar lichen sclerosus.

Mitchell B Berger, Nicholas J Damico, Hope K Haefner

Open access · greenAbstract read
In one paragraph

Article in Journal of lower genital tract disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mitchell B Berger1Pelvic Floor Research Group and 2University of Michigan Center for Vulvar Diseases, Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, MI.
Nicholas J Damico
Hope K Haefner
The Pelvic Floor Institute · USUniversity of Michigan–Ann Arbor · US

Funding

Michigan BIRCWH Career Development ProgramK12HD001438 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHNSON, TIMOTHY RB · 2000 to 2014
$6.7M
NICHD NIH HHS K12 HD001438
6 · The paper itself

Abstract

objectiveThe goal of this study was to test the hypothesis that responses to the McGill Pain Questionnaire are predictive of adjunctive neuropathic pain medication use by women with lichen sclerosus (LS). MATERIALS AND

methodsThis is a retrospective chart review of 430 women with vulvar LS treated at a tertiary referral vulvar care clinic. Demographics, responses to the McGill Pain Questionnaire, and use of neuropathic pain medications were collected. Bivariate and multivariable logistic regression analyses were performed to identify factors significantly associated with use of neuropathic pain medications.

resultsOf the 430 subjects, 119 (27.7%) used neuropathic pain medications for vulvar pain. Factors significantly associated with use of these medications include lower body mass index (odds ratio [OR] = 0.96, p = .02), non-White race (OR = 2.97, p = .05), and total McGill Pain Questionnaire score (OR = 1.05, p < .001).

conclusionsVulvar pain is a common presenting symptom in women with LS. Responses to the McGill Pain Questionnaire may be helpful in the long-term management of women with LS as a screen to identify those patients who might benefit from adjunctive neuropathic pain medication use.

Indexed as

AdolescentAdultAgedAnalgesicsFemaleHumansMiddle AgedNeuralgiaPain MeasurementRetrospective StudiesTertiary Care CentersVulvar Lichen SclerosusYoung AdultAnalgesics

Identifiers

PMID25036743
PMCPMC4297583
OpenAlexW2322679076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.